37.32 USD
+1.18
3.27%
Updated Apr 1, 3:53 PM EDT
1 day
3.27%
5 days
6.63%
1 month
17.62%
3 months
50.42%
6 months
50.12%
Year to date
50.42%
1 year
123.21%
5 years
-23.56%
10 years
33.62%
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 9

150% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 5 (+3) [Q4]

35% more capital invested

Capital invested by funds: $1.1B [Q3] → $1.48B (+$379M) [Q4]

31% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 35

25% more funds holding

Funds holding: 102 [Q3] → 128 (+26) [Q4]

0.59% more ownership

Funds ownership: 4.56% [Q3] → 5.15% (+0.59%) [Q4]

77% less call options, than puts

Call options by funds: $2.92M | Put options by funds: $12.6M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$36
3%
downside
Avg. target
$47
27%
upside
High target
$55
47%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
JP Morgan
Anupam Rama
24% 1-year accuracy
15 / 62 met price target
37%upside
$51
Overweight
Maintained
13 Mar 2025
Scotiabank
Louise Chen
35% 1-year accuracy
48 / 139 met price target
47%upside
$55
Sector Outperform
Initiated
7 Mar 2025
B of A Securities
David Lim
0 / 0 met price target
3%downside
$36
Neutral
Downgraded
3 Mar 2025

Financial journalist opinion

Based on 6 articles about ZLAB published over the past 30 days

Neutral
Business Wire
6 days ago
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company's internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of sarcoma, and ZL-1222, a PD-1 targeted IL-12 immunocytokine for cancer immunotherapy, will be presented during poster sessions at the upcoming American Association for Cancer Research.
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
Positive
Seeking Alpha
1 week ago
Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth
Zai Lab Limited is an innovative Pharma partnering with US and European Pharmas to secure approvals for, and market their drugs in China. ZLAB stock has surged over 105% in the past year, driven by strong revenue growth and ambitious plans for future drug launches. The company aims to achieve $2bn in annual revenues by 2028, with key drugs like Vyvgart and Cobenfy leading the charge.
Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth
Positive
Seeking Alpha
1 week ago
Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
ZLAB's Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. I now consider this IP one of ZLAB's main growth drivers. ZLAB's ongoing strategy of focusing on Chinese approvals continues to pay off with Vyvgart Hytrulo, Xacduro, and Augtyro in oncology and autoimmune diseases. They also have late-stage assets like Bemarituzumab (gastric cancer), KarXT (schizophrenia), and Optune (pancreatic/lung cancer) that could become major revenue verticals in China.
Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
Neutral
Business Wire
2 weeks ago
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. “In China, cervical cancer is a serious health concern with approximately 150,000 new cases diagnosed annually1,”.
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
Positive
Zacks Investment Research
4 weeks ago
Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet
The consensus price target hints at a 64.4% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet
Neutral
Business Wire
4 weeks ago
Zai Lab Announces Participation in Investor Conferences in March 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in March 2025: Leerink Partners 2025 Global Healthcare Conference Fireside Chat: Monday, March 10, 2025, 9:20 a.m. EST Location: Miami, FL Jefferies Biotech on the Beach Summit Time: Tuesday, March 11, 2025 Location: Miami, FL A live webcast of the fireside chat will be available on th.
Zai Lab Announces Participation in Investor Conferences in March 2025
Neutral
Seeking Alpha
1 month ago
Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript
Zai Lab Limited (NASDAQ:ZLAB ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Head of Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado - President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Michael Yee - Jefferies Yen-Der Li - Leerink Partners Reena Patel - Citi Linhai Zhao - Goldman Sachs Li Wang Watsek - Cantor Fitzgerald Po Han Lin - Morgan Stanley Operator Hello, ladies and gentlemen. Thank you for standing by and welcome to Zai Lab's Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript
Negative
Investors Business Daily
1 month ago
China Biotech's Sales Jump 66% But Bottom Line Misses Views
Zai Lab pulled back after the biopharmaceutical reported fourth-quarter results. The biotech is building a cup base.
China Biotech's Sales Jump 66% But Bottom Line Misses Views
Neutral
Business Wire
1 month ago
Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2024, along with recent product highlights and corporate updates. “2024 was a defining year for Zai Lab, marked by strong sales growth, financial strength, and significant pipeline progress. As we look ahead, 2025 is set to be a transformative year with VYVGART's continued momentum, three new product launches, progress with ZL-1310, and.
Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
Positive
Zacks Investment Research
1 month ago
Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?
Zai Lab Limited (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?
Charts implemented using Lightweight Charts™